Breaking News, Trials & Filings

FDA Grants Priority Review to 60 Degrees Pharma

For Tafenoquine (TQ), for the prevention of malaria in adults.

60 Degrees Pharmaceuticals (60P) received Priority Review Designation from the FDA for Tafenoquine (TQ), for the prevention of malaria in adults.     This comes after the January 2018 reception of  Fast Track Designation for the use of Tafenoquine to prevent malaria in adults traveling to areas where the disease is prevalent.      Malaria cases among travelers returning to the U.S. are trending upwards, with 84% of those infected requiring hospitalization.   “We see...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters